For NSCLC patients presenting with BM, knowledge of the driver gene mutation status is particularly important because such as EGFR, ALK, and RET has reported to be the risk factors contributing to BM development in advanced NSCLC17. This evidence concerns the gene ALK and non-small cell lung carcinoma.